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Natural products have long been providing important drug leads for infectious diseases. Leishmaniasis is a major health problem
worldwide that aﬀects millions of people especially in the developing nations. There is no immunoprophylaxis (vaccination)
available for Leishmania infections, and conventional treatments are unsatisfactory; therefore, antileishmanial drugs are urgently
needed. In this work, 48 alcoholic extracts from 46 Cuban plants were evaluated by an in vitro bioassay against Leishmania
amazonensis. Furthermore, their toxicity was assayed against murine macrophage. The three most potent extracts against the
amastigote stage of Leishmania amazonensis were from Hura crepitans, Bambusa vulgaris,a n dSimarouba glauca.
1.Introduction
Leishmaniasis is a protozoan parasitic disease found in 16
developed and 72 developing countries with 12 million
cases [1]; it causes around 70000 deaths annually [2]. So
far, no vaccine approved for human use is available [3].
Various antileishmanial agents are readily available in the
market although none of these chemotherapy drugs are free
from harmful side eﬀects and toxicity [4–7]. Currently, the
development of new drugs against leishmaniasis is a need.
The interest in plants products, specially in medicinal
plants or their extracts, surfaced all over the world due to the
beliefthatmanyherbalextractshavebeenextensivelyusedby
native populations to treat leishmaniasis [8, 9] and scientiﬁc
reports have demonstrated their potential [10, 11]. In the
present study, the antileishmanial activity of 48 extracts from
46 Cuban plants was tested to validate the antiprotozoal
properties of Cuban plants.
2. Methods
2.1. Plant Materials. Vegetative samples of 46 species were
used, and their general data are presented in Table 1.A l l
plants were collected and authenticated according to the
Cuban Flora by M. S. Ram´ on Scull and Dr. Pedro Her-
rera. Their voucher specimens or collector’s numbers were
assigned, and a sample was deposited in a herbarium
(Table 1).
2.2. Preparation of Plant Extracts. The plant organs were
driedinanovenwithventilationsystemat30◦Candcrushed.
T h eﬂ u i de x t r a c t sw e r ep r e p a r e db ym a c e r a t i o nf o rs e v e n
days using 80% ethanol as solvent and 20% water, according
to the Regulation Norm 309 (Regulation Norm, 1992).
Solvent was evaporated, and the extracts were lyophilized
anddissolvedindimethyl-sulfoxide(DMSO,BDH,England)
at 20mg/mL and stored at 4◦C.
2.3. Reference Drug. Pentamidine (Richet, Buenos Aires,
Argentina) was used as positive control and a stock solution
prepared at a concentration of 10mg/mL.
2.4. Parasites. The MHOM/77BR/LTB0016 strain of Leish-
mania amazonensis was kindly provided by the Department
of Immunology, Oswaldo Cruz Foundation (FIOCRUZ),
Brazil. Parasites were routinely isolated by aspiration with
needle from mouse lesions and maintained as promastigotes2 ISRN Pharmacology
Table 1: List of plants used in this study and collections data.
Plants species Family Part used Collection date Geographical areas Voucher specimen
Allium sativum L. Alliaceae Leaves 2006 NBGa, Havana HAJB-HFCc 87089
Aloe barbadensis L. Asphodelaceae Leaves 2010 “La Quiruvina,” Artemisa HACd 42671
Alternanthera sessilis (L.) R. Br. ex DC. Amaranthaceae Leaves 2008 IPFb,H a v a n a H A J B e 87100
Annona glabra L. Annonaceae Leaves 2006 NBG, Havana HAJB 8300098
Argemone mexicana L. Papaveraceae Leaves 2009 IPF HAJB-HFC 87090
Artemisia absinthium L. Asteraceae Leaves 2006 NBG, Havana HAJB 9700183
Artemisia vulgaris L. Asteraceae Leaves 2010 “La Quiruvina,” Artemisa HAC 42673
Azadirachta indica A.Juss Meliaceae Leaves 2008 IPFb, Havana HAJB-HFC 87099
Bambusa vulgaris Schrad. Ex J. C. Wendl. Bambusinae Leaves 2006 NBG, Havana HAJB 9500087
Bambusa vulgaris Schrad. Ex J. C. Wendl. Bambusinae Root 2010 NBG, Havana HAJB 9500087
Bidens pilosa L. Asteraceae Leaves 2006 NBG, Havana HAJB 9700169
Bursera simaruba (L.) Sarg. Burseraceae Leaves 2006 NBG, Havana HAJB 8603305
Cajanus cajan (L.) Millsp. Fabaceae Leaves 2010 “La Quiruvina,” Artemisa HAJB-HFC 42670
Cassia grandis L. Leguminosae Leaves 2006 NBG, Havana HAJB 8300069
Cecropia peltata L. Urticaceae Leaves 2010 NBG, Havana HAJB 8603239
Chenopodium ambrosioides L. Chenopodiaceae Leaves 2010 “La Quiruvina,” Artemisa ROIGe 4639
Cissus sicyoides L. Vitaceae Leaves 2010 NBG, Havana HAJB-HFC 87092
Citrus limetta Risso Rutaceae Leaves 2006 NBG, Havana HAJB-HFC 87093
Cucurbita maxima Dutch. Cucurbitaceae Seeds 2006 NBG, Havana HAJB-HFC 87091
Cupressus sempervirens L. Cupressaceae Leaves 2006 NBG, Havana HAJB 8603788
Curcuma longa L. Zingiberaceae Rhizome 2006 NBG, Havana HAJB 9700178
Cymbopogon citrate Stapf. Poaceae Leaves 2006 NBG, Havana HAJB 8700008
Hura crepitans L. Euphorbiaceae Leaves 2006 NBG, Havana HAJB 8600198
Indigofera suﬀruticosa Mill. Fabaceae Leaves 2006 NBG, Havana HAJB 100079
Koanophyllon villosum (Sw.) King & H. Rob. Asteraceae Leaves 2010 NBG, Havana HAJB-HFC 87094
Lepidium virginicum L. Brassicaceae Leaves 2006 NBG, Havana HAJB 8700259
Luﬀa cylindrica L. Cucurbitaceae Leaves 2006 NBG, Havana HAJB 8600366
Mangifera indica L. Anacardiaceae Leaves 2006 NBG, Havana HAJB 9700183
Melaleuca leucadendron L. Myrtaceae Leaves 2006 NBG, Havana HAJB 8501918
Melia azedarach L. Meliaceae Root 2006 NBG, Havana HAJB 8402273
Momordica charantia L. Cucurbitaceae Leaves 2008 NBG, Havana HAJB 9700180
Ocimum sanctum L. Lamiaceae Leaves 2006 NBG, Havana HAJB 9200485
Parthenium hysterophorus L. Asteraceae Leaves 2006 NBG, Havana HAJB 9700175
Parthenium hysterophorus L. Asteraceae Root 2010 NBG, Havana HAJB 9700176
Petiveria alliaceae L. Phytolaccaceae Leaves 2006 NBG, Havana HAJB 244
Picramnia pentandra Sw. Simaroubaceae Leaves 2006 NBG, Havana HAJB 8303268
Punica granatum L. Punicaceae Fruit bark 2006 NBG, Havana HAJB 8300050
Tradescantia discolor Sw. Commelinaceae Leaves 2005 NBG, Havana HAJB 9200504
Roystonea regia (Kunth) O. F. Cook Arecaceae Leaves 2010 NBG, Havana HFC 87098
Simarouba glauca DC. Simaroubaceae Leaves 2006 NBG, Havana HAJB 8300710
Stachytarpheta jamaicensis (L.) Vahl Simaroubaceae Leaves 2006 NBG, Havana HAJB 9200475
Tabernaemontana citrifolia L. Boraginaceae Leaves 2006 NBG, Havana HAJB 8500720
Tamarindus indica L. Apocynaceae Stem bark 2006 NBG, Havana HAJB 8300068
Thevetia peruviana L. Caesalpiniaceae Leaves 2006 NBG, Havana HAJB-HFC 87095
Trichilia havanensis Jacq. Meliaceae Leaves 2010 NBG, Havana HAJB-HFC 87097
Turnera ulmifolia L. Turneraceae Leaves 2009 NBG, Havana HAJB 8602024
Zerumbet speciosum J. C. Wendl. Zingiberaceae Leaves 2010 NBG, Havana HAJB-HFC 87096
aNBG: the collection of plant was performed in the National Botanic Garden, Havana, Cuba.
bIPF: the collection of plant was performed in the Institute of Pharmacy and Food, Havana, Cuba.
cHFC: Herbarium of National Botanic Garden in the special series of Cuban Flora.
dHAC: Herbarium of Systematic and Ecology Institute.
eHAJB: Herbarium of National Botanic Garden.
fROIG: Herbarium of Experimental Station of Medicinal Plants “Dr. Juan Tom´ as Roig.”ISRN Pharmacology 3
at 26◦C in Schneider’s medium (Sigma-Aldrich, St. Louis,
MO, USA) containing 10% heat-inactivated fetal bovine
serum (HFBS) (Sigma-Aldrich, St. Louis, MO, USA), 100µg
of streptomycin/mL, and 100U of penicillin/mL, with pas-
sage each 3 or 4 days. The parasites were not used after 10
in vitro passages.
2.5. Antipromastigote Screening. Exponentially growing pro-
mastigotes (105 promastigotes/mL, 199µL) were plated in
96-well plates. Two microliters of extracts or 2µLo fD M S O
for control were added to the wells at a ﬁnal concentration
between 6.25 and 100µg/mL. Plates were incubated
at 26◦C for 72h. Then, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO,
USA) solution (15µL) at 5mg/mL dissolved in saline solu-
tion was added to each well. After incubation for additional
4h, the medium was removed and formazan crystals were
dissolved by addition of 100µL of DMSO. Absorbance was
determined using an EMS Reader MF Version 2.4-0, at a
wavelength of 560nm and 630nm as reference [12, 13].
2.6. Cytotoxicity Assay. We determined the IC50 of the ex-
tracts on peritoneal macrophage from BALB/c mice. Resi-
dent macrophages were collected from peritoneal cavity of
healthy BALB/c mice in RPMI 1640 medium (Sigma, St.
Louis, Mo, USA) supplemented with antibiotics (penicillin
200UI, streptomycin 200µg/mL), plated at 106/mL in 96-
well Lab-Tek (Costar, USA) and left to adhere for 2h at 37◦C
in 5% CO2. Nonadherent cells were removed by washing
with saline solution after 2h of incubation at 37◦Ci n5 %
CO2. Then, 198µL of medium with 10% of HFBS and
antibiotics (penicillin 200UI, streptomycin 200µg/mL) was
added in each well, and later 2µL of extracts dilutions,
previously prepared in medium, was added. Macrophages
were treated with the extracts from 1.5 to 200µg/mL for
72h. Cultures with DMSO were included as control treated.
Thecytotoxicitywasdeterminedusingthecolorimetricassay
with MTT as described above in the promastigote assay [13].
2.7. Antiamastigote Activity. Peritoneal macrophages from
BALB/c mice were collected, plated at 106/mL in 24-well
Lab-Tek (Costar, USA), and incubated 2h at 37◦Ci n5 %
CO2. Nonadherent cells were removed, and stationary-phase
L. amazonensis promastigotes were added at a 4:1 para-
site/macrophage ratio. Cultures were added for further 4h,
and cell monolayers were washed to remove free parasites.
Then, 1990µL of the RPMI complete medium and 10µLo f
the diﬀerent extracts were added, following serial dilutions
1:2, to obtain ﬁnal concentrations between 12.5 and
100µg/mL. Plates were incubated for a further 48h [14].
Cultures as control were included, which were treated with
DMSO. Cultures were then ﬁxed with absolute methanol,
stained with Giemsa, and examined under light microscopy.
The number of intracellular amastigotes was determined by
counting the amastigotes resident in 100 macrophages per
each sample. Results were expressed as percent of re-
duction of the infection rate (% IR) in comparison with
those obtained with positive controls. The infection rates
were obtained by multiplying the percentage of infected
macrophages by the number of amastigotes per infected
macrophages [15].
2.8. Statistic Analysis. All tests were performed in triplicate,
and the median inhibitory concentration (IC50) to parasite
and median cytotoxic concentration (CC50)t op e r i t o n e a l
macrophage from BALB/c mice were obtained directly from
linear equation of dose-response curves. The results were
expressed as their average and standard deviation.
TheactiveextractsthatshowedanIC50 <100µg/mLwere
selectedasactiveagainstpromastigoteform,andcytotoxicity
was determined. Then, the selectivity index (SI), calculated
as ratio of CC50 for macrophage/IC50 for promastigotes, was
used to compare the toxicity and activity of the extracts.
The extracts with an SI more than 5 were tested against the
amastigote form. The extracts with an IC50 ≤ 50µg/mL were
considered as active against intracellular amastigotes of
Leishmania.
3. Results
TheactivityofextractsagainstL.amazonensispromastigotes,
the cytoxicity against peritoneal macrophage from BALB/c
mice, and the selectivity are shown in Table 2. Between them,
20 extracts showed activity, with an IC50 < 100µg/mL,
although only 4 extracts (Bambusa vulgaris, Hura crepitans,
Mangifera indica, and Simarouba glauca) demonstrated
selective activity against the parasite and were tested against
intracellular amastigotes.
AmongthefourextractsevaluatedagainstL.amazonensis
amastigotes, three showed inhibition of growth with IC50 ≤
50µg/mL. The highest antileishmanial activity was exhibited
by H. crepitans, with the lower IC50 value (27.7±0.6µg/mL).
TheIC50 ofB.vulgarisandS.glaucawas41.5±0.6µg/mLand
45.5 ± 0.3µg/mL, respectively. M. indica extract showed an
IC50 value of 60.1 ±3.3µg/mL.
4. Discussion
Natural products are potential sources of new and selective
agents for the treatment of important tropical diseases
caused by protozoan and other parasites [16]. Only few
laboratories are involved in drug evaluation and develop-
ment against these devastating diseases, particularly against
leishmaniasis, which has been considered as a “neglected
disease” [17]. In this sense, the potential of plant products as
asourceofantileishmanialdrugshasbeendemonstratedand
considered as a promising approach. Several studies about
screening of plants extracts against Leishmania have been
reported [18–23].
Diﬀerent models to evaluate drugs have been used,
including promastigote, intracellular amastigote, or axenic
amastigote forms of the parasite. The most important
method is the counting of intracellular amastigotes, which
are the clinical relevant stage of Leishmania in the mam-
malian host. Conventional procedures involve staining with
Giemsa after treatment and manual counting. However,4 ISRN Pharmacology
Table 2: Antileishmanial activity and cytotoxicity of Cuban plants extracts.
Plants species IC50
a ± SDb (µg/mL) CC50
c ± SD (µg/mL) SId
A. sativum 153.2 ± 2.1 — —
A. barbadensis 77.5 ± 0.9 150.3 ± 3.4 2
A. sessilis >200 — —
A. glabra 37.8 ± 0.1 — —
A. mexicana >200 — —
A. absinthium 129.0 ± 1.5 — —
A. vulgaris 55.0 ± 3.2 107.7 ± 5.1 2
A. indica >200 — —
B. vulgaris (leaves) 60.5 ± 7.3 276.5 ±1.2 5
B. vulgaris (root) 191.6 ± 1.1 — —
B. pilosa 73.7 ± 0.1 222.8 ± 1.1 3
B. simaruba 163.3 ± 1.8
C. cajan 51.7 ± 0.7 132.5 ± 5.7 3
C. grandis >200 — —
C. peltata >200 — —
C. ambrosioides >200 — —
C. sicyoides >200 — —
C. limetta 73.6 ± 1.3 210.6 ± 3.9 3
C. maxima 62.2 ± 0.1 161.7 ± 0.9 3
C. sempervirens >200 — —
C. longa >200 — —
C. citrate >200 — —
H. crepitans 16.4 ± 2.1 390.5 ±8.6 24
I. suﬀruticosa 75.8 ± 4.5 158.5 ± 6.2 2
K. villosum >200 — —
L. virginicum 109.7 ± 1.8 — —
L. cylindrica 127.9 ± 1.0 — —
M. indica 51.2 ± 0.1 442.4 ±2.9 9
M. leucadendron 57.2 ± 2.9 199.2 ± 4.7 3
M. azedarach 168.6 ± 1.9 — —
M. charantia 59.8 ± 0.4 26.7 ± 0.3 0
O. sanctum 96.9 ± 0.1 216.9 ± 4.8 2
P. hysterophorus (leaves) 54.7 ± 1.2 89.2 ± 1.5 0
P. hysterophorus (root) 46.9 ± 1.7 140.2 ± 0.2 3
P. alliaceae 151.5 ± 4.1 — —
P. pentandra 140.8 ± 1.4 — —
P. oleracea 63.9 ± 2.6 125.9 ± 1.9 2
P. granatum 39.4 ± 8.8 129.0 ± 4.6 3
R. spathacea 71.4 ± 1.4 244.6 ± 1.6 3
R. regia >200 — —
S. glauca 47.5 ± 0 228.7 ±8.0 5
S. jamaicensis 111.8 ± 1.2 — —
T. citrifolia >200 — —
T. indica >200 — —
T. peruviana >200 — —
T. havanensis >200 — —
T. ulmifolia >200 — —
Z. speciosum 133.1 ± 0.8 — —
Pentamidine 0.37 ± 0.01 11.7 ± 1.7 32
aIC50: concentration of drug that caused 50% of growth inhibition of promastigotes of L. amazonensis.
bSD: standard deviation.
cCC50: concentration of drug that caused 50% of mortality of peritoneal macrophage from BALB/c.
dSI: selectivity index. Bold data indicate the extract selected.ISRN Pharmacology 5
this conventional procedure has limitations such as being
time consuming, the use of animals for extraction of
macrophages, and the possible error in the counting. Axenic
amastigotes forms have been developed to obtain a more
simpleandreproduciblemethod.Thesearetechnicallyeasier
and less expensive and require a very shorter time for
execution. However, this model lacks information about the
behaviorofmacrophagesduringthetreatment,theirpossible
inﬂuenceondrugactivity,orpossibledamagereceiveddueto
toxicity [24]. Alternatively, the promastigote form has been
used in screening investigations. Although it is not a clinical
relevant stage, it was reported that this parasitic form gives
information on speciﬁc antileishmanial activity respect to
toxicity showed (selectivity of the product). In addition, the
tests are easy and highly reproducible [22]. The use of the
promastigote form has been widely demonstrated as the
preliminary test in screening of plant extract [8, 25, 26].
As part of a screening project of natural plants against
protozoanparasites,wetested48extractsagainstLeishmania,
which were selected according to the previous literature that
mentioned these plants with antiparasitic properties [27]. In
addition, the evaluatedplants present an easycultivation and
can be obtained in high quantities of samples.
Cuba presents a rich plant population that has been
unexploited in the ﬁeld of antiprotozoals. Nevertheless, pre-
vious studies about antileishmanial potentialities of Cuban
plants were reported, including Chenopodium ambrosioides
[28], Piper auritum [29], and Bidens pilosa [23]. We found
that 42% (20 extracts) of the tested products showed leish-
manicidal activity with an IC50 ≤ 100µg/mL against pro-
mastigotes, of which only 20% (4 extracts) exhibited selec-
tivity (SI > 5) and of them 75% (3 extracts) caused growth
inhibition in the antiamastigote assay.
Among the plant species evaluated here, H. crepitans
causedthehigherinhibition ofpromastigotesgrowth(IC50 =
16.4µg/mL) and lower toxicity against host cell (IC50 =
390.5µg/mL), with an SI = 24. This plant showed the
highest activity with an IC50 = 27.7µg/mL against the
amastigote form. The results demonstrated the presence
of compounds with reasonable potency. H. crepitans is a
native plant from tropical America that has been used for
amoebiasistreatment[30]andagainstotherprotozoasuchas
Plasmodium falciparum [31]. In Nicaragua, this plant is used
to treat helmintic diseases as ascariasis [30] and in Loreto,
Peru, is used by the population to treat the leishmaniasis
[8] with acceptable eﬃcacy. In addition, this extract has
shown promising activity against P. falciparum [32], with a
low toxicity and a SI > 10. In the literature uses of its seeds
are reported as emmenagogue although they can cause toxic
eﬀects, including the death of patients [33]. The toxicity of
this plant is caused by two toxic albumins (toxalbumins),
hurina and crepitina, which are distributed among all plant
organs [34, 35].
On the other hand, the leaves extract from B. vulgaris
showedanIC50 =60.49µg/mLagainstthepromastigoteform
and SI = 5, while the activity was better against the amastig-
ote form, with an IC50 = 41.5µg/mL. However the root
extract of this species did not show antileishmanial activity,
which would be due to the diﬀerential distribution of
metabolites in the plant. This ﬁnding should indicate that
the component(s) responsible for leishmanicidal activity is
(are) found in a major percent in the leaves, resulting in
the parasite inhibition presented. B. vulgaris is an original
tropical plant from Old World that has been cultivated
in America [27]. Previously, it has been reported that B.
vulgaris leave extract was inactive in a diﬀerent screening
approach because the extract was dissolved in ethanol [23].
This demonstrates the importance of the dissolvent in the
screening approaches. DMSO is a membrane permeabiliser
and is known for its ability to serve as carried to transport
the drugs into cells [36]. Additionally, this extract has shown
activity against other protozoa, such as P. falciparum [32].
Other uses include antiparasitic preventive control for dogs
[37], cuts, injuries, and swellings [38] and as diuretic in
the east population of Cuba [27]. Chemical analysis of B.
vulgaris leave extract revealed the presence of diﬀerent bioac-
tive components, including: alkaloids, tannins, phenolics,
glycosides, saponins, ﬂavonoids, and anthraquinones [39]
S. glauca also showed a promising antileishmanial activity.
The IC50 against promastigotes was similar to that against
amastigotes (IC50 of 47.5 and 45.5µg/mL, resp.) and an SI
of 5 was obtained. This plant is present in Latin America and
has been used for diﬀerent purposes, for example, in Cuba
as emmenagogue, febrifuge, antidysenteric, antihelmintic,
and antiherpetic [27], in Hait´ ı for the cutaneous lesions
[40], and in Guatemala against malaria and amoebiasis [41].
The glaucarrubin is a terpenoids, present in this plant, has
been described as responsible for the activity against Gram-
positive bacteria and protozoa parasite, specially Entoameba
histolytica and P. falciparum [40].
Several reports in the literature have shown the antileish-
manial activity of some plant extracts, including the hidroal-
coholic extract from C. ambrosioides [42]a n dOcimum
sanctum [43]. However, we did not observe antileishmanial
activity of these plants in this study. This apparent con-
troversial result can be due to the variation of chemical
components between plants from diﬀerent geographic areas,
whichhavebeendocumented[44],includingplantsfromthe
same country [9].
5. Conclusion
Insum,inthisstudy,48Cubanplantsextractswereevaluated
against L. amazonensis. The extracts of H. crepitans, B.
vulgaris,a n dS. glauca showed promising antileishmanial ac-
tivity against life cycle stages of the parasite and high selec-
tivity compared with the activity against mouse peritoneal
macrophages. For this reason the next step should be the
puriﬁcation and identiﬁcation of the active principles of
these plants.
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